Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Parkinson's Disease

    Ohio

    Search
    Parkinson's Disease
    Ohio
    Show Map
    Map View
    Ohio
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      86 Parkinson's Disease Trials near Ohio

      Power is an online platform that helps thousands of Parkinson's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Tavapadon for Parkinson's Disease

      Dayton, Ohio
      This trial is testing a medication called tavapadon to see if it is safe and effective for people with Parkinson's Disease. The medication aims to help manage symptoms like tremors and stiffness by targeting specific parts of the brain.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Suicidal Ideation, Others
      Must Be Taking:Levodopa/carbidopa

      992 Participants Needed

      Bemdaneprocel for Parkinson's Disease

      Ann Arbor, Michigan
      Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:45 - 75

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Stroke, Cancer, Others
      Must Be Taking:Levodopa

      102 Participants Needed

      ND0612 for Parkinson's Disease

      Cleveland, Ohio
      This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30 - 80

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Severe Dyskinesias, Others
      Must Be Taking:Levodopa

      381 Participants Needed

      CVN424 for Parkinson's Disease

      Columbus, Ohio
      This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Severe Dyskinesias, Heart Disease, Others
      Must Be Taking:Levodopa

      330 Participants Needed

      ABBV-951 Infusion for Parkinson's Disease

      New Albany, Ohio
      Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Unsuitable Candidate, Others

      118 Participants Needed

      Apomorphine Infusion for Parkinson's Disease

      Cincinnati, Ohio
      This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      99 Participants Needed

      BHV-8000 for Parkinson's Disease

      Cleveland, Ohio
      A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:40 - 85

      Key Eligibility Criteria

      Disqualifiers:Other Parkinsonian Syndromes, CNS Disease, Smokers, Others
      Must Not Be Taking:PD Medications

      550 Participants Needed

      CREXONT ER for Parkinson's Disease

      Cleveland, Ohio
      The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Prior Neurosurgical Treatment, Others
      Must Be Taking:CD-LD

      220 Participants Needed

      Personalized Real-Time Deep Brain Stimulation for Parkinson's Disease

      Cleveland, Ohio
      A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling. The ultimate goal of this study is to inform the development of closed-loop neuromodulation technology that can be programmed and adjusted in real time based on patient-specific neural activity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Secondary Parkinsonism, Stroke, Others
      Must Be Taking:Levodopa

      25 Participants Needed

      Pimavanserin vs. Quetiapine for Psychosis in Parkinson's Disease

      Cleveland, Ohio
      Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in up to 60% of PD patients at some point in time. Parkinson's disease psychosis can sometimes be associated with decreased quality of life, increased nursing home placement, increased rate of death, and greater caregiver burden. There are approximately 50,000 Veterans with Parkinson's disease receiving care in the VA, and up to 30,000 (60%) of them will experience psychosis at some point in time. Quetiapine is an antipsychotic drug approved by the Food and Drug Administration (FDA) that is the most commonly used medication to treat PD psychosis, but more studies are needed to determine if it works for this condition and is also well tolerated and safe. Pimavanserin is a newer antipsychotic drug approved by the Food and Drug Administration (FDA) specifically to treat PD psychosis, but more studies are needed to determine if it works and its safety. The purpose of this research is to gather additional information on the safety and effectiveness of both Quetiapine and Pimavanserin. By doing this study, the investigators hope to learn which of these medications is the most effective course of treatment for people with PD psychosis. Enrollment is open to Veterans nationwide, see your VA provider about the possibility of being referred to one of the study's Hub sites. This can be done through contact from your provider to the study's NSC (Tamara Boney at 267-303-9829).
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Severe Psychosis, Schizophrenia, Others
      Must Not Be Taking:Antipsychotics, CYP3A4 Inducers, Others

      358 Participants Needed

      IPX203 for Parkinson's Disease

      Cleveland, Ohio
      The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Severe Dyskinesia, Dementia, Others
      Must Be Taking:Levodopa

      22 Participants Needed

      Zoledronic Acid for Parkinson's Disease

      Columbus, Ohio
      This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Hip Fracture, Non-ambulatory, Kidney Dialysis, Others
      Must Not Be Taking:Bisphosphonates, SERMs, Denosumab

      2650 Participants Needed

      tES Device for Parkinson's Disease

      Cleveland, Ohio
      This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head. Participants will use the device at home for 13 minutes each weekday (Monday through Friday) for 3 weeks, then be monitored for another 3 weeks without treatment. The entire study lasts 6 weeks and is conducted virtually through video calls and online assessments. The investigators will measure changes in Parkinson's symptoms using standard rating scales and video recordings of movement tasks like walking and hand tremor tests. Participants will also record videos of their movements at home using their smartphone or computer. The study includes 30 adults aged 18-80 who have been diagnosed with Parkinson's disease and have stable medication for at least 4 weeks. Participants must have reliable internet access and be able to follow the treatment schedule. The main goal is to see if this brain stimulation treatment can reduce motor symptoms like tremor, stiffness, and slowness of movement. The investigators will also check if any improvements last after treatment ends and monitor for any side effects. All participants receive the active device treatment - there is no placebo group. The device has been tested in over 250 people in previous studies with no serious adverse events reported
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Recent Stroke, Cognitive Impairment, Others

      30 Participants Needed

      Tributyrin for Parkinson's Disease Dementia

      Ann Arbor, Michigan
      The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation. The main questions it aims to answer are: 1. Does tributyrin improve memory/thinking test scores and walking/balance ability? 2. What medical problems do participants have when taking tributyrin? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no drug) to see if tributyrin works to treat Parkinson disease symptoms. Participants will: 1. Take tributyrin 3 times a day for 80-100 days 2. Complete motor and cognitive testing at the clinic before and after the supplementation period 3. Complete brain imaging (MRI scans and PET scans) before and after the supplementation period.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:45+

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Large Vessel Stroke, Uncontrolled GI Disease, Significant Metabolic Comorbidity, Suicidal Ideation, Others
      Must Not Be Taking:Anti-cholinergics

      45 Participants Needed

      RNDP-001 Implant for Parkinson's Disease

      Columbus, Ohio
      This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:45 - 75

      Key Eligibility Criteria

      Disqualifiers:Gene Mutation, Previous Surgery, Others

      12 Participants Needed

      NE3107 for Parkinson's Disease

      Canton, Ohio
      The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:45 - 80

      Key Eligibility Criteria

      Disqualifiers:Major Mental, Physical Illness, Others
      Must Not Be Taking:Levodopa

      60 Participants Needed

      Varenicline for Parkinson's Disease

      Ann Arbor, Michigan
      This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:45+

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonian, Stroke, Epilepsy, Others
      Must Not Be Taking:Dopamine Blockers, Anticholinergics

      102 Participants Needed

      BIA 28-6156 for Parkinson's Disease

      South Euclid, Ohio
      This trial is testing a new drug called BIA 28-6156 to see if it can slow down movement problems in people with Parkinson's disease who have a specific genetic mutation. The study will compare the drug to another treatment over a period of several months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:35 - 80

      Key Eligibility Criteria

      Disqualifiers:Gaucher's Disease, LRRK2 Variant, Others
      Must Be Taking:PD Medications

      237 Participants Needed

      IkT-148009 for Parkinson's Disease

      Columbus, Ohio
      This trial tests the safety and effects of IkT-148009, a daily pill, in people aged 30 to 80 with untreated Parkinson's disease. The drug aims to block an enzyme that may help manage symptoms. Participants will take the drug for a few months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:30 - 80

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Hallucinations, Substance Abuse, Others
      Must Not Be Taking:Antipsychotics, Amphetamines, Levodopa, Others

      120 Participants Needed

      Citalopram for Parkinson's Disease

      Ann Arbor, Michigan
      This trial will test if taking citalopram for a long period can reduce harmful brain plaques in older adults with Parkinson's disease. The goal is to see if this can help prevent or slow down memory and thinking problems. The study involves patients aged 65 and older who do not have depression. Citalopram has been observed to improve motor performance in Parkinson's disease patients when combined with levodopa.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Stroke, Depression, Others
      Must Not Be Taking:Neuroleptics, Antidepressants

      58 Participants Needed

      Why Other Patients Applied

      "My dad was in a research group for Parkinson's for about 6 years, which was very interesting. I was just diagnosed 1.5 years ago, and started on low dose Sinemet. Doing well on Sinemet, but I'd like to get ahead of the condition. I'm excited about participating in research. "

      LN
      Parkinson's PatientAge: 74

      "I wasn’t diagnosed until February, but I showed symptoms over ten years before. I want to help find a cure. I have lost family members to Parkinson’s and want to contribute to the search for better treatments before my children possibly come down with it."

      YX
      Parkinson's PatientAge: 61

      "I have 5 kids. I'll do anything I can to slow this disease down in hopes that I can stay active with them into their adulthood. I also feel I am serving the greater good for all those who suffer from Parkinson's. Since I'm self employed, my schedule is flexible. "

      UR
      Parkinson's PatientAge: 53

      "It seems my Parkinson’s is progressing more rapidly now. And my meds are lagging behind. My off time is more frequent and the episodes are longer. Trying to figure out what my options are."

      TM
      Parkinson's PatientAge: 58

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Parkinson's Disease Trial

      NEU-411 for Parkinson's Disease

      Columbus, Ohio
      The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Secondary Parkinsonian Syndromes, Uncontrolled Diabetes, Others

      150 Participants Needed

      BIIB122 for Early-Stage Parkinson's Disease

      Cleveland, Ohio
      This trial is testing a new drug called BIIB122 to see if it can slow down symptoms in people with early-stage Parkinson's disease. The drug works by blocking a protein that may cause the disease to get worse. Participants will take the drug for several years to see if it helps.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:30 - 80

      Key Eligibility Criteria

      Disqualifiers:Stroke, Dementia, Seizure, Others

      650 Participants Needed

      Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease

      Cincinnati, Ohio
      This trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Acute Psychosis, Others
      Must Be Taking:Levodopa, Carbidopa

      214 Participants Needed

      Gene Therapy for Parkinson's Disease

      Columbus, Ohio
      The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:45 - 75

      Key Eligibility Criteria

      Disqualifiers:Vascular Disease, Cognitive Impairment, Psychosis, Others
      Must Be Taking:Antiparkinsonian

      87 Participants Needed

      GDNF Gene Therapy for Parkinson's Disease

      Columbus, Ohio
      The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:35 - 75

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Dementia, Psychosis, Others
      Must Be Taking:Levodopa

      11 Participants Needed

      Physical Therapy + Medication for Parkinson's Disease

      Cleveland, Ohio
      Gait and balance problems are a significant source of disability in patients with Parkinson disease. Physical therapy remains one of the main treatments. On the other hand some medications, such as methyphenidate and atomoxetine, have been tried with promising results. The outcomes in gait and balance in Parkinson disease after a combination of physical therapy and the medications mentioned above have not been explored yet. The investigators want to evaluate whether the addition of medication, either low dose of methylphenidate or atomoxetine, to physical therapy will achieve improvement in gait and balance in Parkinson disease more than physical therapy alone. The investigators propose a pilot, single center, rater blind, prospective randomized trial. 2-arm-parallel group, intention-to-treat analysis.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Epilepsy, Cardiac Arrhythmia, Others
      Must Be Taking:Dopaminergic Therapy

      42 Participants Needed

      Deep Brain Stimulation for Parkinson's Disease

      Cleveland, Ohio
      This study employs an exploratory, prospective, single center, naturalistic clinical trial design with a randomized crossover intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Stroke, Multiple Sclerosis, Dementia, Others

      10 Participants Needed

      Aerobic Exercise for Parkinson's Disease

      Cleveland, Ohio
      The proposed multi-site, Genetics and Aerobic Exercise to Slow PD (GEARS) Trial will, for the first time, determine the interplay between genetics and exercise in altering PD progression. In sum, 200 PD patients will be recruited from the Cleveland and Salt Lake City metro areas to participate in the Pedaling for Parkinson's (PFP) community-based exercise program. Participants will exercise at community-based sites 3x/week for 12 months. All participants will undergo genotyping using an array that includes the genome backbone and common risk variants associated to increase risk for multiple neurological disorders including PD.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Neurocognitive Impairment, Others
      Must Be Taking:Anti-parkinsonian

      200 Participants Needed

      Exercise for Parkinson's Disease

      Cleveland, Ohio
      This trial involves people with Parkinson's Disease doing two types of stationary bike exercises. One type is where they pedal at their own pace, and the other is where they are helped to pedal faster. The goal is to see if higher intensity exercise can improve their symptoms more effectively.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Neurocognitive Impairment, Musculoskeletal Issues, Others

      25 Participants Needed

      Exercise for Parkinson's Disease

      Cleveland, Ohio
      Fifteen PwPD who have undergone DBS surgery and utilize the Percept system will complete a FE and VE exercise session on a stationary cycle while Off antiparkinsonian medication. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre-, during FE or VE and post-exercise). The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III Motor Exam and upper extremity force-tracking task will be used to determine motor response to exercise.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Neurocognitive Impairment, Musculoskeletal Issues, Others

      15 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Parkinson's Disease clinical trials in Ohio pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Parkinson's Disease clinical trials in Ohio work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Parkinson's Disease trials in Ohio 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Ohio for Parkinson's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Ohio several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Parkinson's Disease medical study in Ohio?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Parkinson's Disease clinical trials in Ohio?

      Most recently, we added Accelerated Brain Stimulation for Parkinson's Disease, Deep Brain Stimulation for Parkinson's Disease and Tributyrin for Parkinson's Disease Dementia to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Glioblastoma Clinical Trials near Miami, FL

      Top Clinical Trials near Memphis, TN

      Top Clinical Trials near Bonita Springs, FL

      195 Clinical Trials near Hawthorne, NY

      Top Depression Clinical Trials near Philadelphia, PA

      191 Clinical Trials near Keller, TX

      65 Weight Loss Trials near San Antonio, TX

      Top Clinical Trials near Cordele, GA

      28 Bipolar Disorder Trials near Los Angeles, CA

      17 Glaucoma Trials near Glendale, AZ

      179 Clinical Trials near Harrisburg, NC

      Top Neck Pain Clinical Trials

      By Trial

      CAR T-cell Therapy for Acute Lymphoblastic Leukemia

      Apalutamide + ADT for Prostate Cancer

      Roflumilast Cream for Eczema

      Skin Substitutes + Standard Care for Diabetic Foot Ulcers

      Nivolumab + Ipilimumab for Melanoma

      Nature-based Intervention for Chronic Pain

      ViPOR-P for B-Cell Lymphoma

      Rhenium Liposome Treatment for Brain Cancer

      PF-07328948 for Heart Failure

      Lisocabtagene Maraleucel for Lymphoma

      PCV13 + CAR T-Cell Therapy for Lymphoma

      Risk-Directed Therapy for Medulloblastoma